Pura Vida Investments LLC bought a new position in shares of BioDelivery Sciences International, Inc. (NASDAQ:BDSI) during the fourth quarter, Holdings Channel reports. The firm bought 622,922 shares of the specialty pharmaceutical company’s stock, valued at approximately $2,305,000. BioDelivery Sciences International accounts for approximately 1.4% of Pura Vida Investments LLC’s holdings, making the stock its 23rd biggest holding.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Advisor Group Inc. lifted its position in shares of BioDelivery Sciences International by 56.3% in the fourth quarter. Advisor Group Inc. now owns 10,943 shares of the specialty pharmaceutical company’s stock valued at $40,000 after acquiring an additional 3,943 shares in the last quarter. Worth Venture Partners LLC purchased a new stake in shares of BioDelivery Sciences International in the third quarter valued at $167,000. Raymond James & Associates lifted its position in shares of BioDelivery Sciences International by 14.9% in the fourth quarter. Raymond James & Associates now owns 46,211 shares of the specialty pharmaceutical company’s stock valued at $171,000 after acquiring an additional 6,000 shares in the last quarter. Dimensional Fund Advisors LP purchased a new stake in shares of BioDelivery Sciences International in the third quarter valued at $255,000. Finally, Wells Fargo & Company MN lifted its position in shares of BioDelivery Sciences International by 121.7% in the third quarter. Wells Fargo & Company MN now owns 118,060 shares of the specialty pharmaceutical company’s stock valued at $331,000 after acquiring an additional 64,803 shares in the last quarter. Institutional investors own 57.02% of the company’s stock.

Several analysts have recently issued reports on the company. HC Wainwright restated a “buy” rating and issued a $6.00 price objective on shares of BioDelivery Sciences International in a research report on Friday. Cantor Fitzgerald restated a “buy” rating and issued a $8.00 price objective on shares of BioDelivery Sciences International in a research report on Thursday. BidaskClub upgraded BioDelivery Sciences International from a “sell” rating to a “hold” rating in a research report on Wednesday, February 20th. Janney Montgomery Scott restated a “buy” rating and issued a $5.00 price objective on shares of BioDelivery Sciences International in a research report on Thursday, January 31st. Finally, Zacks Investment Research upgraded BioDelivery Sciences International from a “hold” rating to a “strong-buy” rating and set a $4.75 price objective on the stock in a research report on Wednesday, January 23rd. Two research analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $5.55.

In related news, Director Francis E. Odonnell, Jr. sold 8,000 shares of the company’s stock in a transaction on Friday, February 1st. The stock was sold at an average price of $4.60, for a total value of $36,800.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Francis E. Odonnell, Jr. sold 23,000 shares of the company’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $5.07, for a total value of $116,610.00. Following the completion of the transaction, the director now owns 544,187 shares of the company’s stock, valued at $2,759,028.09. The disclosure for this sale can be found here. Insiders sold 50,175 shares of company stock worth $215,265 over the last 90 days. Company insiders own 13.26% of the company’s stock.

Shares of NASDAQ:BDSI opened at $4.98 on Friday. The company has a current ratio of 3.00, a quick ratio of 2.77 and a debt-to-equity ratio of 1.42. BioDelivery Sciences International, Inc. has a 52-week low of $1.70 and a 52-week high of $5.21. The firm has a market capitalization of $352.63 million, a PE ratio of -12.77 and a beta of 0.45.

COPYRIGHT VIOLATION WARNING: This story was first reported by Watch List News and is the property of of Watch List News. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this story can be viewed at https://www.watchlistnews.com/pura-vida-investments-llc-buys-new-stake-in-biodelivery-sciences-international-inc-bdsi/2896898.html.

About BioDelivery Sciences International

BioDelivery Sciences International, Inc is a pharmaceutical company, which engages in the development and commercialization of new applications of approved therapeutics to address important unmet medical needs. It focuses on pharmaceutical products in the areas of pain management and addiction. The company was founded on January 6, 1997 and is headquartered in Raleigh, NC.

See Also: How prevalent are 12b-1 fees?

Want to see what other hedge funds are holding BDSI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioDelivery Sciences International, Inc. (NASDAQ:BDSI).

Institutional Ownership by Quarter for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.